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Abstract
Background: Thromboembolism is one of the main causes of maternal mortality, which can be prevented in many
cases. The present study was designed to investigate the incidence and prophylaxis strategies for maternal
mortality following thromboembolism in postnatal.
Methods: In this case series study, the data of the mortality cases were extracted according to the ethical and
security standards of the Ministry of Health of the country and compared with a healthy control group. The
thromboembolism risk factors measured and scored using a questionnaire entitled “the evaluation of risk factors for
maternal mortality following thromboembolism during pregnancy, labor, or post-partum”.
Results: The maternal mortality rate was 16 per 100,000 live births. Among 297 mortality cases, 27 (9%) death were
due to thromboembolism. The mean gestational age was 32.5 weeks. Dyspnea (88.8%) and tachycardia (18.5%)
were found as common clinical manifestations in these patients. Sixteen cases (59.3%) did not get heparin, 6
(22.2%) received single dose and 5 (18.5%) received two doses and more. In these 11 cases, 5 (45%) patients
received heparin before surgery, 1 after surgery, and 5 before and after surgery. Twenty cases deceased in the first
hours after delivery and the rest after 2 to 12 days. The average score of risk for thromboembolism based on Royal
College of Obstetricians & Gynecologist (RCOG) guideline was 4.6.
Conclusion: It seems that one of the most important cause of maternal mortality in this study was the lack of
recognition of high-risk patients and the lack of prescription for prophylaxis with heparin and this clearly explains
the need for accurate screening of high-risk mothers, designing a standard form and the care and treatment of
these patients.
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Introduction
Maternal mortality is one of the greatest tragedies with
wide ranging consequences for the family and society [1].
It is an important public health indicator that reflects both
the quality of health care services and the women’s status
[2, 3]. Reduction of maternal mortality serves as one of
the most important international development goals [4].
Several factors such as gravidity, type of delivery, socioeco-
nomic status was found as the most important determi-
nants of maternal mortalities in the region [3].
Primary causes of maternal mortality in U. S include
infection, cardiac disease, hemorrhage, thrombo-
embolism and hypertensive disorders [5]. Iran has
also experienced a transition pattern in its major
causes of maternal mortality and morbidity from
those characteristics of developing nations such as
hemorrhage and infection to causes more commonly
seen in developed nations including thromboembol-
ism, cardiac diseases [6–8] and in not rare condition,
post-operative complications [9]. Accurate recogni-
tion and attention on maternal mortality is critical to
have an effective prevention [10].
Pregnancy is a prothrombotic and temporary condi-
tion that increase the risk of venous thromboembolism
(VTE) four to five times as compared to non-pregnant
women [11, 12]. The risk of venous thromboembolism is
higher in women ages 35; Thrombophilia, lupus, cardiac
disease, sickle cell disease, obesity, fluid and electrolyte
imbalance, postpartum infection and transfusion are the
other significant risk factors [11]. Many cases of VTE
occur during the first trimester of pregnancy and the
risk increases with progression of gestational age and
reaches the maximum after delivery [13].
The incidence rate of thromboembolic events related
to pregnancy is 3 people per 1000 cesarean and also sug-
gests that cesarean delivery is associated with a fourfold
increase in the risk of VTE incidence compared with
vaginal delivery [14]. Women with preeclampsia are at
risk of treating thromboembolic events, three times
more than healthy women, in the postpartum period.
There is also a correlation between smoking and the
increased risk of VTE [15].
The most common signs were dyspnea at first and tachy-
cardia in the second grade. Although these symptoms can be
completely similar in other illnesses such as heart disease or
bleeding, but it indicates that these symptoms should con-
sider in pregnant women. On the other hand, these two
signs seem to be the most endearing signs of the disease, and
in order to prevent maternal mortality, it should be deter-
mined by accurate screening of high-risk mothers at an earl-
ier stage. An X-ray of chest helps to exclude other causes
that lead to dyspnea and tachycardia [16].
Therefore, thromboembolism risk assessment should
be performed at any time during pregnancy; in early
pregnancy and specially at delivery and if risk factors
change, or in cases with medical or surgical conditions
[17]. Identification of these factors is important and may
reduce the incidence and improve its timely diagnosis.
In the current study we estimate the incidence, risk
factors, and mortality from pregnancy-related venous
thromboembolism.
Materials and methods
In this retrospective study cases with thromboembol-
ism coded as the underlying or contributory cause of
death in women aged 15–44 from March 2017 to
February 2018 were evaluated. This national data was
obtained from ministry of health which records
maternal mortality statistics throughout the country,
therefore no case would miss in this era. We included
all women with fatal VTE occurred during pregnancy
or within 6 weeks post-partum, according to the
definition of maternal death. Medical records, autopsy
reports and data from the Ministry of Health were
examined in order to detect contributing factors for
VTE.
Obstetrical information such as parity, pregnancy and
delivery complications. Were retrieved either. The study
protocol was approved by the local ethics committee of
Tehran University of Medical Sciences. Patient records
extracted in accordance with the ethical and security
guidelines of the Ministry of Health and the risk factors
of thromboembolism measured using a questionnaire
entitled “Risk factors for thromboembolism during preg-
nancy and puerperium” that is summarized with the
scores based on Royal College of Obstetricians &
Gynecologist (RCOG) guideline [18] in Table 1. The
scores will gather to reach a total value.
If total score is 4 or more, anticoagulant administration
with prophylaxis dose starts from the beginning of the
pregnancy. In score 3, it is recommended to start anti-
coagulant with prophylactic dosage from the 28th week of
pregnancy. If total score is 2 or more postnatally or admit-
ted to hospital antenatally, consider thromboprophylaxis
for at least 10 days. In prolonged hospitalization (≥ 3 days)
or readmission to hospital within the puerperium, con-
sider thromboprophylaxis either [18].
Statistical analysis
Mean (SD) (standard deviation) and percentage of
frequency were calculated for descriptive objectives. The
data were analyzed by the SPSS version 18.
Results
The maternal mortality rate was 16 per 100,000 live
births. Among 297 mortality cases in 1 year, 27 deaths
were due to thromboembolism. The mean (SD) age was
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33.2 (3.3) years and the mean of gestational age was 33
weeks+ 6 days.
Two cases with mortality in the first day were not
recognized and the symptoms were misdiagnosed with
postpartum pain and distress. Dyspnea (88.8%) and
tachycardia (18.5%) were the common manifestations in
these patients. The diagnosis of all cases was confirmed
by autopsy. Demographic and clinical data of the cases
are listed in Table 2.
There were no any case of family history for thrombo-
embolism, hospitalized or immobilized (≥3 days rest in
bed), dehydration, ovarian hyperstimulation syndrome,
surgery during pregnancy or postpartum, hyperemesis
gravidarum, nephropathy disorders, smoking, intravenous
drug addiction, inflammatory bowel disease and sickle cell
disease among these patients.
The mean (SD) of thromboembolism score was 4.6
(1.9). Nine patients had score < 4 and 18 patients ≥4.
Heparin prescription frequencies based on different rea-
sons are listed in Table 3.
The rate of mortality with the history of VTE, anti-
phospholipid syndrome and inherited thrombophilia was
Table 1 The evaluation of risk factors for thromboembolism during pregnancy and puerperium
Risk Factors Score
A) Risk factors related to general conditions
Body mass index (BMI) equal to or greater than 40 (before or during early pregnancy) 2
Age older than 35 years 1
BMI between 35 and 40 (before or early pregnancy / weight greater than 80 kg) 1
Parity ≥ 3 regardless of the current pregnancy 1
Smoking 1
Gross varicose veins (symptomatic or above the knee or with phlebitis, edema, skin changes) 1
B) Risk factors related to medical conditions
History of previous VTE (except for the reason of major surgery) 4
Acquired thrombophilia (antiphospholipid antibody syndrome): at least one laboratory test and at least a clinical criterion 4
History of previous VTE due to major surgery 3
Any medical conditions: cancer, cardiac disease, active lupus, inflammatory poly-arthropathy or inflammatory bowel disease,
nephrotic syndrome, type 1 diabetes mellitus with nephropathy, tuberculosis, current intravenous drug addiction
3
High risk inherited thrombophilia (deficiency of anti-thrombin, protein S or C deficiency, homozygote low risk thrombophilia
or more than one heterozygote low risk thrombophilia)
3
Low risk inherited thrombophilia (heterozygote factor 5 Leiden, G20210A prothrombin gene mutation) 1
Family history of VTE in first degree relatives (spontaneous or estrogen dependent) 1
Anti-phospholipid antibodies (only laboratory criteria, without a clinical criteria) 1
C) Obstetrical Risk Factors
Cesarean section in labor 2
Current preeclampsia 1
Pregnancy with fertility IVF / ART methods (only considered during pregnancy) 1
Multiple pregnancy 1
Non-emergency cesarean (elective) 1
Instrumental delivery 1
Prolonged labor (more than 24 h) 1
Postpartum hemorrhage (greater than 1 l / blood transfusion) 1
Preterm labor (less than 37 weeks) in the current pregnancy 1
Intrauterine fetal demise (IUFD) in the current pregnancy 1
D) Transient Risk Factors
Ovarian hyper stimulation syndrome (only in the first trimester) 4
Surgery during pregnancy or postpartum (curettage, tubal closure, appendectomy..., except for perineal immediate repair) 3
Severe vomiting of pregnancy (hyperemesis) 3
Systemic infections (antibiotics or admission needed) foe example: pneumonia, pyelonephritis, postpartum wound infection 1
Hospitalization or immobilization (≥3 days rest in bed), dehydration 1
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Table 2 Demographic and clinical data of the cases deceased
due to thromboembolism
variable N (%)
Type of hospital Educational 21 (77.8)
Private 5 (18.5)
Charity 1 (3.7)
BMIa < 30 23 (85.2)
30–40 4 (14.8)
≥ 40 0








Delivery Type NVDb 6 (22.2)
CSc Emergency 7 (25.9)
Elective 14 (51.9)
Parity ≥3 10 (37)
< 3 17 (63)
Infant gender Male 14 (51.9)
Female 13 (48.1)






Death time Morning shift 18 (66.7)
Evening shift 9 (33.3)






Blood transfusion Yes 11 (40.7)
No 16 (59.3)
Heparin prescription Yes Single dose 6 (22.2)
multiple doses 5 (18.5)
No 16 (59.3)
Time of Heparin prescription Before surgery 5 (18.5)
After surgery 1 (3.7)
Before & after surgery 5 (18.5)
Table 2 Demographic and clinical data of the cases deceased
due to thromboembolism (Continued)
variable N (%)
None 16 (59.3)
Preterm labor Yes 13 (48.1)
No 14 (51.9)
IUFDd Yes 7 (25.9)
No 20 (74.1)
Postpartum hemorrhage Yes 7 (25.9)
No 20 (74.1)
Prolonged labor Yes 1 (3.7)
No 26 (96.3)
Instrumental delivery Yes 2 (7.4)
No 25 (92.6)
Sepsis Yes 3 (11.1)
No 24 (88.9)
Multiple pregnancy Yes 3 (11.1)
No 24 (88.9)
IVF/ARTe Yes 4 (14.8)
No 23 (85.2)
Antiphospholipid syndrome Yes 1 (3.7)
No 26 (96.3)
Cardiac Disease Yes 8 (29.6)
No 19 (70.4)
Hypothyroidism Yes 1 (3.7)
No 26 (96.3)
Cancer Yes 1 (3.7)
No 26 (96.3)
Diabetes Yes 4 (14.8)
No 23 (85.2)
Rheumatoid disease Yes 1 (3.7)
No 26 (96.3)
Hereditary thrombophilia Yes 1 (3.7)
No 26 (96.3)
Preeclampsia Yes 1 (3.7)
No 26 (96.3)
Chronic hypertension Yes 3 (11.1)
No 24 (88.9)
Thromboembolism history Yes 1 (3.7)
No 26 (96.3)
abody mass index, bnormal vaginal delivery, ccesarean section, dintra uterine
fetal demise, ein vitro fertilization/ assisted reproductive technology
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one in each group and all 3 received heparin as prophylaxis.
There were 3 cases with sepsis and none of them got
heparin.
In Table 4 we broke down the VTE events including
timing and VTE score in each case.
We also compared the variables between the cases and
a healthy control group and found out some variables
including sepsis (p = 0.020), preterm labor (p = 0.002),
stillbirth (p = 0.001), postpartum hemorrhage (p = 0.005),
number of delivery (3 or more) (P = 0.016), blood
transfusion (P = 0.003) and cardiac disease (P = 0.00)
were significantly more in case group. Other variables
were not significantly different between groups.
Discussion
In this study, the risk factors for thromboembolism were
investigated in 27 mortality cases due to mentioned reason.
The mean gestational age was 33 weeks+ 6 days and nearly
half of the cases experienced premature births. This is the
same reason as Simpson et al. study that reported delivery
at gestational age < 36 as a risk factor for VTE [19].
The use of risk score calculator may effectively and
safely determine the duration of heparin therapy [18].
Darguad et al. indicated that in patients with moderate
risk of VTE (score = 3–5), prescription of heparin
prophylaxis in the third trimester prevent thrombosis
[20]. In our study, the mean score of the thromboembol-
ism (retrograde calculation) was 4.6 suggesting that
these cases were a high-risk population for thrombo-
embolic events; however only half of them with score
more than 4 cases received heparin. There were some
deliveries in deprived areas with no access to score
calculation; therefore the Ministry of Health designed a
single form to add the clinic and hospital records of each
pregnant woman. Every center is obligated to calculate
this score to decrease adverse events. This score will
reevaluate in prenatal visit, delivery time and postpartum
period.
Although the age of 35 years in pregnant women is
associated with an increased risk of thromboembolic
events [18], in this study the average age of the cases was
33.2 years that may reveal the impact of other variables to
increase the risk of thromboembolism. Although
Danilenko-Dixon et al. also reported no correlation
between age and VTE in pregnancy and puerperium
period [21].
More than 70% of cases have embolized in first day
after delivery and about one half of them deceases intra-
partum. Since more than half of them did not even
Table 3 Heparin prescription frequencies based on different
reasons
variable Heparin+ Heparin−
N (%) N (%)
Total score < 4 2 (22.2) 7 (77.8)
Total score ≥ 4 9 (50.0) 9 (50.0)
Death in morning shift 2 (22.2.0 7 (77.8)
Death in night shift 9 (50.0) 9 (50.0)
Normal Vaginal Delivery 3 (50.0) 3 (50.0)
Cesarean Section 8 (38.1) 13 (61.9)
Body Mass Index < 30 11 (40.7) 12 (59.3)
Body Mass Index ≥ 30 0 4 (100)
Parity ≥ 3 4 (40.0) 6 (60.0)
Parity < 3 7 (42.2) 10 (58.8)
Cardiac Disease Yes 4 (50.0) 4 (50.0)
No 7 (36.8) 12 (63.2)
Preterm Labor Yes 6 (46.2) 7 (53.8)
No 5 (36.8) 9 (64.3)
Heparin + means heparin did prescribed
Heparin _ means heparin did not prescribed
Table 4 Timing and numbers of VTE score in each case




























*VTE score based on ACOG criteria
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receive a single dose of heparin, the need to quickly and
accurately identify the indications of prophylactic treat-
ment with heparin or other preventive methods to
reduce mortality in these mothers is obvious.
Available data suggests that the risk of VTE is higher
after cesarean section than vaginal delivery [22]. The
indications for cesarean and the conditions during/after
the surgery could be involved in the occurrence of
thromboembolism and possibly mortality. The puerperium
is the time of maximal risk of pregnancy-associated VTE
and several observational studies have assessed the risk of
VTE after cesarean section [23–25].
Blondon et al. accounted maternal Body mass index
(BMI) as an important risk factor for postpartum VTE,
grading from weak in overweight women to very strong
in women with class III obesity [26]. However, in the
other study, BMI was not related to VTE. This is similar
to our result that BMI was in few patients above or
equal to 30 and in none of the mortalities more than 40.
Women with inherited thrombophilia or a positive
family history even with no previous episode of VTE,
have a risk of developing a first VTE episode in preg-
nancy or postpartum period [27]. The highest risks were
associated with homozygosity for factor V Leiden or the
prothrombin G20210A variant [28]. In the present
survey, one case had a history of VTE, one with an anti-
phospholipid antibody syndrome, and the other with
hereditary thrombophilia that all received heparin.
Thromboembolism happened may be due to not
receiving proper dosage of heparin.
Low molecular heparin is the preferred option for
prophylaxis in most patients because of its better bio-
availability, longer plasma half-life, more predictable
dose response, and improved maternal safety [29, 30].
Also heparin is more effective than vitamin K antago-
nists in preventing recurrent VTE and post-thrombotic
syndrome without increasing the risk of major bleeding
events [31].
In our study, the most frequent blood group of
mothers was A +. The study of Mirza Aghazadeh et al.
also had the highest reports of VTE associated with the
A + blood group [32]; Although this blood group gener-
ally has a high prevalence in Iran [33]. On the other
population-based study blood groups A and AB were
associated with increased risk estimates for VTE in preg-
nancy and the puerperium either [34].
Thirty-seven percent of mothers had more than 3
times delivery, 30% had heart disease, 21% had high
blood pressure and 25% had stillbirth, it seems that these
factors have a significant effect on the risk of maternal
conditions.
Frequency of multiple pregnancy, severe bleeding,
instrumental delivery, pregnancy by assisted reproduct-
ive techniques, prolonged delivery, sepsis, preeclampsia,
and underlying illness were observed in less than 30% of
these 27 mothers and showed that although these factors
are predisposed to the occurrence of thrombotic events,
but they do not contribute much to our study.
There are studies on the prevalence of risk factors and
etiology of maternal mortality that explain rupture of
membrane and severe bleeding are important risk
factors in thromboembolism; therefore, precise follow-
up and, if necessary, preventive and interventional pro-
ceedings may be effective in preventing maternal deaths.
Conclusion
The study concludes that a high proportion of maternal
mortality following thromboembolism are potentially
preventable. It is suggested that pregnant women should
be carefully evaluated for these risk factors, and that
health care personnel and pregnant mothers should be
trained to diagnose the early symptoms, as well as pre-
vention and treatment of thromboembolic events.
The use of more accurate diagnostic methods for rapid
diagnosis and control of the disease, as well as postpar-
tum care, particularly in high-risk individuals, including
women over 35 years of age, a history of more than three
times pregnancy, a history of VTE, and the administra-
tion of prophylactic heparin with a sufficient dose and
duration, decrease maternal mortality.
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